Dublin, April 21, 2026 (GLOBE NEWSWIRE) — The “EGFR Non-Small Cell Lung Cancer Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The report offers comprehensive insights including market size, regional shares, and competition analysis, equipping stakeholders with essential data to navigate this rapidly evolving industry. Enhanced personalized medicine approaches and innovative therapeutic developments continue to propel the market, promising improved patient care and outcomes.
The EGFR non-small cell lung cancer market has experienced robust growth, with an increase from $9.34 billion in 2025 to an expected $10.07 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historic period growth can be attributed to factors such as increasing prevalence of non-small cell lung cancer, advancements in molecular diagnostics, heightened awareness of EGFR mutation testing, the expansion of oncology specialty centers, and broader availability of targeted therapies.
The market is anticipated to continue its upward trajectory, reaching approximately $13.74 billion by 2030 at a CAGR of 8.1%. This forecasted growth is driven by factors including the expanding pipeline of next-generation EGFR inhibitors, increased adoption of precision oncology methods, and the growing integration of real-world evidence in cancer care. Personalized medicine is playing a significant role by allowing for treatment strategies tailored to individual genetic profiles, thereby enhancing patient outcomes. Notably, in February 2024, the FDA approved 16 new personalized therapies for rare diseases, a significant increase from the preceding year.
Industry leaders like AstraZeneca PLC are focusing on innovative treatments to reduce side effects and enhance therapeutic effectiveness. For instance, AstraZeneca announced in June 2025 that its drug Datroway (datopotamab deruxtecan) received approval in the US for treatment of advanced EGFR-mutated non-small cell lung cancer. Similarly, Daiichi Sankyo is collaborating with Merck Co. Inc. to develop new antibody-drug conjugates for this market, amplifying treatment options available to patients.
Despite tariffs impacting costs related to importing active pharmaceutical ingredients and diagnostics, these challenges are also fostering regional drug manufacturing and research. This shift is expected to enhance local production and support economic expansion through increased investment in domestic oncology R&D.
Major companies such as Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, and Bayer are prominent in this sector, focusing on developing and commercializing cutting-edge therapies. The sector is characterized by a range of therapies including tyrosine kinase inhibitors and monoclonal antibodies, addressing various mutation types and administered in diverse formats like monotherapy and combination therapy.
Report Scope:
- Markets Covered: Drug Types like Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies; Mutation Types including Exon 19 Deletions; Treatment Types such as Monotherapy; Routes like Oral administration; End Users including hospitals and oncology centers.
- Subsegments: Categories within TKIs and Monoclonal Antibodies, and late-phase therapies.
- Companies Mentioned: Key industry players like Johnson & Johnson, AstraZeneca, and prominent pharmaceutical companies globally.
- Countries: Key markets like the USA, China, Germany, and emerging Asian economies.
- Regions: Coverages include Asia-Pacific, Western Europe, and more.
- Time Series and Data: Historical and forecast data, market shares, and competitor analysis.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $10.07 Billion |
| Forecasted Market Value (USD) by 2030 | $13.74 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
The companies featured in this EGFR Non-Small Cell Lung Cancer market report include:
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Pfizer Inc.
- AstraZeneca PLC
- Bayer AG
- Eli Lilly and Company
- Takeda Pharmaceuticals Company Ltd.
- Boehringer Ingelheim Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Co. Ltd.
- Taiho Pharmaceutical Co. Ltd.
- Jiangsu Hansoh Pharmaceutical Co. Ltd.
- Betta Pharmaceuticals Co. Ltd.
- ShanghAI Allist Pharmaceuticals Co. Ltd.
- Oric Pharmaceuticals Inc.
- Black Diamond Therapeutics Inc.
- G1 Therapeutics Inc.
- Dizal Pharmaceutical
- ArriVent BioPharma Inc.
- Cullinan Therapeutics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/qnrxwf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- EGFR Non-Small Cell Lung Cancer Market
